10x Genomics Reports $150.7 million in Latest Quarterly Results
10x Genomics reported quarterly results highlighted by Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025., according to its earnings release filed with an 8-K Thursday.
Revenue was $150.7 million for the third quarter of 2026, as compared to $149.0 million for the corresponding period of 2025. Revenue increased 1% over the corresponding period of 2025. Revenue was $150.7 million. r of 2026, a 3% decrease from $132.5 million.
Results detail
Further figures in the release included revenue guidance and now expects revenue in the range of $625 million to $635 million, versus the; Operating expenses were $129.0 million for the third quarter of 2026, a 3% decrease from $132.5 million for the corresponding prior year period. The decrease was primarily driven by lower personnel and lab equipment expenses, partially offset by higher litigation expenses; Revenue increased 1% over the corresponding period of 2025.
The filing is an Item 2.02 results announcement furnished with Exhibit 99.1. Comparisons use the year-earlier period as presented by 10x Genomics unless the release specifies another baseline. Where both GAAP and non-GAAP metrics appear, both are summarized when the extract includes them.
Segment mix, cash flow and any outlook language in the release are the usual secondary reads after the headline revenue and earnings figures.
Why it matters
For retail investors, the 10x Genomics print is a check on whether growth, margins and cash generation are moving together. The figures above come from the company’s Exhibit 99.1 earnings materials; how they stack up against the prior-year run rate and any guide published with the release will shape the near-term debate.
By the numbers
- Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025.
- Revenue was $150.7 million for the third quarter of 2026, as compared to $149.0 million for the corresponding period of 2025. Revenue increased 1% over the corresponding period of 2025.
- Revenue was $150.7 million
- r of 2026, a 3% decrease from $132.5 million
- revenue guidance and now expects revenue in the range of $625 million to $635 million, versus the
- Operating expenses were $129.0 million for the third quarter of 2026, a 3% decrease from $132.5 million for the corresponding prior year period. The decrease was primarily driven by lower personnel and lab equipment expenses, partially offset by higher litigation expenses.
Sources
- 10x Genomics, Inc. Form 8-K with quarterly financial results, filed Nov. 5, 2026 (accession 0001628280-26-071025)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.